Elysium Therapeutics, Inc.

Elysium is executing a capital-efficient strategy to disrupt the $10B+ Rx opioid pain market by developing a new class of Rx opioids that are designed to (i) protect against fatal oral and non-oral overdose; (ii) disrupt the progression to Rx and illicit opioid abuse and addiction; and (iii) provide patients with effective pain relief.